A Cross-Sectional Study to Assess Walking Performance in Subjects With Peripheral Artery and End Stage Kidney Disease
Completed
Conditions studied: Peripheral Artery Disease, End Stage Renal Disease on Dialysis
In brief
A cross-sectional, non-interventional study to assess walking performance, vascular function, and lower limb calcification in subjects with peripheral artery disease and end-stage kidney disease (PAD-ESKD) receiving hemodialysis.
Key facts
- Study ID
- NCT04487301
- Run by
- Sanifit Therapeutics S. A.
- People needed
- 36
- Starts
- 2020-11-16
- Expected to finish
- 2021-06-12
- Last updated by the study team
- 2021-10-14
Who can join
Age: 45 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- ≥55 years of age or ≥45 years of age with diabetes
- Receiving maintenance HD in a clinical setting for at least 2 weeks prior to screening
- Resting ABI <0.90 in either leg OR Resting TBI <0.70 in either leg
- Symptomatic as characterized by a limitation in exercise performance
You may not qualify if…
- Above-ankle amputation
- Chronic limb-threatening ischemia (Rutherford 4-6)
- Non-ambulatory status
- A condition other than PAD that limits ability to walk
- Open or endovascular revascularization within 3 months prior to baseline.
- Illnesses, conditions, or planned surgeries within the study period that will interfere with the interpretation of the study results
Where it is running
- Valley Renal Medical Group — Northridge, California, United States
- Horizon Medical Research — Coral Gables, Florida, United States
- Brigham and Women's Hospital — Boston, Massachusetts, United States
- Boston Medical Center — Boston, Massachusetts, United States
- St Louis Kidney Care — St Louis, Missouri, United States
- Mountain Kidney & Hypertension Associates — Asheville, North Carolina, United States
- Houston Medical Research — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.